Milestone Alert: First Person Dosed in Alys’ Phase 1/1b Study of ALY-301 for Cold Urticaria
The first subject has been dosed in Alys Pharmaceuticals, Inc.’s Phase 1/1b study of ALY-301, a first-in-class mast cell selective c-Kit inhibitor for the treatment of cold urticaria.